Baidu
map

Expert Rev Anti Infect Ther:抗MRSA的喹诺酮类药物治疗ABSSSIs的效果与其他抗生素类似

2022-05-31 sunshine MedSci原创

临床实践中常会遇到急性细菌性皮肤和皮肤结构感染(ABSSSIs),其临床表现包括蜂窝组织炎、红斑狼疮、重大皮肤脓肿和伤口感染。

临床实践中常会遇到急性细菌性皮肤和皮肤结构感染(ABSSSIs),其临床表现包括蜂窝组织炎、红斑狼疮、重大皮肤脓肿和伤口感染。一些随机对照试验(RCTs)比较了抗MRSA的喹诺酮类药物与其他常规使用的抗生素在治疗ABSSSIs方面的临床疗效,然而目前还缺乏对这些抗MRSA喹诺酮类药物在治疗ABSSSIs患者中的作用的集合分析。近日,发表于Expert Rev Anti Infect Ther的一项系统回顾和荟萃分析比较了抗耐甲氧西林金黄色葡萄球菌(MRSA)喹诺酮类药物治疗ABSSSIs 的临床疗效和安全性。

研究人员检索了PubMed、Embase和Cochrane中央对照试验登记册中截止至2021年7月21日收录的比较抗MRSA喹诺酮类药物与其他抗生素治疗成人ABSSSI患者的临床疗效和安全性的RCTs。

 

结果,研究共纳入了6项RCTs,包括1264名接受了基于抗MRSA喹诺酮的受试者(研究组)和1307名受试者(对照组)。在接受抗MRSA喹诺酮类治疗的研究组中,935名、246名和83名患者分别接受了德拉沙星、左旋咪唑和阿可乐沙星治疗。分析结果显示,研究组和对照组在测试治愈率方面没有明显差异(OR,1.08;95%CI,0.91-1.29;I2 = 0%)。在MRSA相关的ABSSSIs患者中,抗MRSA喹诺酮类药物的临床治愈率(OR,1.09;95% CI,0.71-1.65;I2 = 0%)和微生物学反应率(OR,1.24;95% CI,0.48-3.21;I2 = 0%)与其他抗生素相似。

综上所述,该研究结果表明,在治疗ABSSSI方面,以抗MRSA喹诺酮为基础的治疗的疗效与其他抗MRSA抗生素相当。此外,抗MRSA的喹诺酮类药物至少与其他治疗方法一样可以耐受。

 

原始出处:

 

Chien-Ming Chao, et al., Anti-MRSA quinolones for acute bacterial skin and skin structure infection: a systematic review and meta-analysis of randomized controlled trials. Expert Rev Anti Infect Ther. 2022 May;20(5):733-739. doi: 10.1080/14787210.2022.2004119.   

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1928461, encodeId=ec7f1928461a7, content=<a href='/topic/show?id=3cf54018620' target=_blank style='color:#2F92EE;'>#喹诺酮#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40186, encryptionId=3cf54018620, topicName=喹诺酮)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=917c196, createdName=sjzlzc007, createdTime=Wed Jun 08 20:16:03 CST 2022, time=2022-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2054879, encodeId=156820548e92b, content=<a href='/topic/show?id=250012241d8' target=_blank style='color:#2F92EE;'>#mRS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12241, encryptionId=250012241d8, topicName=mRS)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/7F67E3BE360D6DD1D0A62E3E71E23CB6/100, createdBy=9d8a2500148, createdName=ms8888626721583891, createdTime=Wed Jun 15 02:16:03 CST 2022, time=2022-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2024027, encodeId=4fab202402edc, content=<a href='/topic/show?id=5eb31e808d' target=_blank style='color:#2F92EE;'>#ABSSSI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1780, encryptionId=5eb31e808d, topicName=ABSSSI)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e729101, createdName=huanbaofeng, createdTime=Thu Dec 08 06:16:03 CST 2022, time=2022-12-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1649450, encodeId=5b34164945094, content=<a href='/topic/show?id=081a16e10e8' target=_blank style='color:#2F92EE;'>#SSI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16710, encryptionId=081a16e10e8, topicName=SSI)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=586523824746, createdName=nymo, createdTime=Tue Aug 09 08:16:03 CST 2022, time=2022-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1729575, encodeId=e8761e29575a5, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Wed Apr 12 21:16:03 CST 2023, time=2023-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1393757, encodeId=4e7c1393e575c, content=<a href='/topic/show?id=ccc412243db' target=_blank style='color:#2F92EE;'>#MRSA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12243, encryptionId=ccc412243db, topicName=MRSA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce072500140, createdName=12498b3em08(暂无昵称), createdTime=Thu May 19 05:16:03 CST 2022, time=2022-05-19, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1928461, encodeId=ec7f1928461a7, content=<a href='/topic/show?id=3cf54018620' target=_blank style='color:#2F92EE;'>#喹诺酮#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40186, encryptionId=3cf54018620, topicName=喹诺酮)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=917c196, createdName=sjzlzc007, createdTime=Wed Jun 08 20:16:03 CST 2022, time=2022-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2054879, encodeId=156820548e92b, content=<a href='/topic/show?id=250012241d8' target=_blank style='color:#2F92EE;'>#mRS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12241, encryptionId=250012241d8, topicName=mRS)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/7F67E3BE360D6DD1D0A62E3E71E23CB6/100, createdBy=9d8a2500148, createdName=ms8888626721583891, createdTime=Wed Jun 15 02:16:03 CST 2022, time=2022-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2024027, encodeId=4fab202402edc, content=<a href='/topic/show?id=5eb31e808d' target=_blank style='color:#2F92EE;'>#ABSSSI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1780, encryptionId=5eb31e808d, topicName=ABSSSI)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e729101, createdName=huanbaofeng, createdTime=Thu Dec 08 06:16:03 CST 2022, time=2022-12-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1649450, encodeId=5b34164945094, content=<a href='/topic/show?id=081a16e10e8' target=_blank style='color:#2F92EE;'>#SSI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16710, encryptionId=081a16e10e8, topicName=SSI)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=586523824746, createdName=nymo, createdTime=Tue Aug 09 08:16:03 CST 2022, time=2022-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1729575, encodeId=e8761e29575a5, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Wed Apr 12 21:16:03 CST 2023, time=2023-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1393757, encodeId=4e7c1393e575c, content=<a href='/topic/show?id=ccc412243db' target=_blank style='color:#2F92EE;'>#MRSA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12243, encryptionId=ccc412243db, topicName=MRSA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce072500140, createdName=12498b3em08(暂无昵称), createdTime=Thu May 19 05:16:03 CST 2022, time=2022-05-19, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1928461, encodeId=ec7f1928461a7, content=<a href='/topic/show?id=3cf54018620' target=_blank style='color:#2F92EE;'>#喹诺酮#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40186, encryptionId=3cf54018620, topicName=喹诺酮)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=917c196, createdName=sjzlzc007, createdTime=Wed Jun 08 20:16:03 CST 2022, time=2022-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2054879, encodeId=156820548e92b, content=<a href='/topic/show?id=250012241d8' target=_blank style='color:#2F92EE;'>#mRS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12241, encryptionId=250012241d8, topicName=mRS)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/7F67E3BE360D6DD1D0A62E3E71E23CB6/100, createdBy=9d8a2500148, createdName=ms8888626721583891, createdTime=Wed Jun 15 02:16:03 CST 2022, time=2022-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2024027, encodeId=4fab202402edc, content=<a href='/topic/show?id=5eb31e808d' target=_blank style='color:#2F92EE;'>#ABSSSI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1780, encryptionId=5eb31e808d, topicName=ABSSSI)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e729101, createdName=huanbaofeng, createdTime=Thu Dec 08 06:16:03 CST 2022, time=2022-12-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1649450, encodeId=5b34164945094, content=<a href='/topic/show?id=081a16e10e8' target=_blank style='color:#2F92EE;'>#SSI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16710, encryptionId=081a16e10e8, topicName=SSI)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=586523824746, createdName=nymo, createdTime=Tue Aug 09 08:16:03 CST 2022, time=2022-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1729575, encodeId=e8761e29575a5, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Wed Apr 12 21:16:03 CST 2023, time=2023-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1393757, encodeId=4e7c1393e575c, content=<a href='/topic/show?id=ccc412243db' target=_blank style='color:#2F92EE;'>#MRSA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12243, encryptionId=ccc412243db, topicName=MRSA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce072500140, createdName=12498b3em08(暂无昵称), createdTime=Thu May 19 05:16:03 CST 2022, time=2022-05-19, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1928461, encodeId=ec7f1928461a7, content=<a href='/topic/show?id=3cf54018620' target=_blank style='color:#2F92EE;'>#喹诺酮#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40186, encryptionId=3cf54018620, topicName=喹诺酮)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=917c196, createdName=sjzlzc007, createdTime=Wed Jun 08 20:16:03 CST 2022, time=2022-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2054879, encodeId=156820548e92b, content=<a href='/topic/show?id=250012241d8' target=_blank style='color:#2F92EE;'>#mRS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12241, encryptionId=250012241d8, topicName=mRS)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/7F67E3BE360D6DD1D0A62E3E71E23CB6/100, createdBy=9d8a2500148, createdName=ms8888626721583891, createdTime=Wed Jun 15 02:16:03 CST 2022, time=2022-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2024027, encodeId=4fab202402edc, content=<a href='/topic/show?id=5eb31e808d' target=_blank style='color:#2F92EE;'>#ABSSSI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1780, encryptionId=5eb31e808d, topicName=ABSSSI)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e729101, createdName=huanbaofeng, createdTime=Thu Dec 08 06:16:03 CST 2022, time=2022-12-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1649450, encodeId=5b34164945094, content=<a href='/topic/show?id=081a16e10e8' target=_blank style='color:#2F92EE;'>#SSI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16710, encryptionId=081a16e10e8, topicName=SSI)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=586523824746, createdName=nymo, createdTime=Tue Aug 09 08:16:03 CST 2022, time=2022-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1729575, encodeId=e8761e29575a5, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Wed Apr 12 21:16:03 CST 2023, time=2023-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1393757, encodeId=4e7c1393e575c, content=<a href='/topic/show?id=ccc412243db' target=_blank style='color:#2F92EE;'>#MRSA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12243, encryptionId=ccc412243db, topicName=MRSA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce072500140, createdName=12498b3em08(暂无昵称), createdTime=Thu May 19 05:16:03 CST 2022, time=2022-05-19, status=1, ipAttribution=)]
    2022-08-09 nymo
  5. [GetPortalCommentsPageByObjectIdResponse(id=1928461, encodeId=ec7f1928461a7, content=<a href='/topic/show?id=3cf54018620' target=_blank style='color:#2F92EE;'>#喹诺酮#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40186, encryptionId=3cf54018620, topicName=喹诺酮)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=917c196, createdName=sjzlzc007, createdTime=Wed Jun 08 20:16:03 CST 2022, time=2022-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2054879, encodeId=156820548e92b, content=<a href='/topic/show?id=250012241d8' target=_blank style='color:#2F92EE;'>#mRS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12241, encryptionId=250012241d8, topicName=mRS)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/7F67E3BE360D6DD1D0A62E3E71E23CB6/100, createdBy=9d8a2500148, createdName=ms8888626721583891, createdTime=Wed Jun 15 02:16:03 CST 2022, time=2022-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2024027, encodeId=4fab202402edc, content=<a href='/topic/show?id=5eb31e808d' target=_blank style='color:#2F92EE;'>#ABSSSI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1780, encryptionId=5eb31e808d, topicName=ABSSSI)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e729101, createdName=huanbaofeng, createdTime=Thu Dec 08 06:16:03 CST 2022, time=2022-12-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1649450, encodeId=5b34164945094, content=<a href='/topic/show?id=081a16e10e8' target=_blank style='color:#2F92EE;'>#SSI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16710, encryptionId=081a16e10e8, topicName=SSI)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=586523824746, createdName=nymo, createdTime=Tue Aug 09 08:16:03 CST 2022, time=2022-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1729575, encodeId=e8761e29575a5, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Wed Apr 12 21:16:03 CST 2023, time=2023-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1393757, encodeId=4e7c1393e575c, content=<a href='/topic/show?id=ccc412243db' target=_blank style='color:#2F92EE;'>#MRSA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12243, encryptionId=ccc412243db, topicName=MRSA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce072500140, createdName=12498b3em08(暂无昵称), createdTime=Thu May 19 05:16:03 CST 2022, time=2022-05-19, status=1, ipAttribution=)]
    2023-04-12 feather89
  6. [GetPortalCommentsPageByObjectIdResponse(id=1928461, encodeId=ec7f1928461a7, content=<a href='/topic/show?id=3cf54018620' target=_blank style='color:#2F92EE;'>#喹诺酮#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40186, encryptionId=3cf54018620, topicName=喹诺酮)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=917c196, createdName=sjzlzc007, createdTime=Wed Jun 08 20:16:03 CST 2022, time=2022-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2054879, encodeId=156820548e92b, content=<a href='/topic/show?id=250012241d8' target=_blank style='color:#2F92EE;'>#mRS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12241, encryptionId=250012241d8, topicName=mRS)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/7F67E3BE360D6DD1D0A62E3E71E23CB6/100, createdBy=9d8a2500148, createdName=ms8888626721583891, createdTime=Wed Jun 15 02:16:03 CST 2022, time=2022-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2024027, encodeId=4fab202402edc, content=<a href='/topic/show?id=5eb31e808d' target=_blank style='color:#2F92EE;'>#ABSSSI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1780, encryptionId=5eb31e808d, topicName=ABSSSI)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e729101, createdName=huanbaofeng, createdTime=Thu Dec 08 06:16:03 CST 2022, time=2022-12-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1649450, encodeId=5b34164945094, content=<a href='/topic/show?id=081a16e10e8' target=_blank style='color:#2F92EE;'>#SSI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16710, encryptionId=081a16e10e8, topicName=SSI)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=586523824746, createdName=nymo, createdTime=Tue Aug 09 08:16:03 CST 2022, time=2022-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1729575, encodeId=e8761e29575a5, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Wed Apr 12 21:16:03 CST 2023, time=2023-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1393757, encodeId=4e7c1393e575c, content=<a href='/topic/show?id=ccc412243db' target=_blank style='color:#2F92EE;'>#MRSA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12243, encryptionId=ccc412243db, topicName=MRSA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce072500140, createdName=12498b3em08(暂无昵称), createdTime=Thu May 19 05:16:03 CST 2022, time=2022-05-19, status=1, ipAttribution=)]

相关资讯

Int J Cardiol:氟喹诺酮类药物与主动脉病变风险

由此可见,该研究结果表明当前使用氟喹诺酮药物与主动脉瘤和夹层风险增加显著相关。卫生保健提供者需要了解这种严重的关联,并明智地使用氟喹诺酮类药物,以尽量减少主动脉病严重后遗症的风险。

BMJ:口服氟喹诺酮类药物不会增加严重心律失常的风险

该研究的目的是评估是否口服氟喹诺酮类药物的使用与严重心律失常风险增加相关。原始出处:Malin Inghammar,Henrik Svanström,Mads Melbye,et al.Oral fluoroquinolone use and serious arrhythmia,BMJ,2016.2.26

JAMA Intern Med:氟喹诺酮类药物增加了主动脉瘤或夹层的风险

氟喹诺酮类药物与胶原降解相关,这些抗生素的使用提高人们对相关的更严重的胶原性疾病安全性的关注,包括主动脉瘤和主动脉夹层。该研究的目的是调查氟喹诺酮治疗和显影主动脉瘤和夹层的风险之间的关系。研究人员在2000年1月和2011年12月对来自台湾国民健康保险研究数据库(NHIRD)的1477病例患者和147700匹配的参与者进行了一项巢式病例对照研究,这些参与者来自1亿人的纵向观察群体。病例患者被定义为

J Infect:氟喹诺酮类药物常规用于结核性脑膜炎 不推荐!不推荐!不推荐!

现代生活方式节奏的加快,打破了很多人的生活规律和习惯,患结核性脑膜炎的人逐渐增多。早期使用抗结核治疗,辅助皮质类固醇,可以降低结核性脑膜炎的死亡率和致残率,然而,仍有接近一半的患者死亡或者留下严重残疾。因此,寻找新药来改善这些患者的结局十分有必要。

Baidu
map
Baidu
map
Baidu
map